These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31642056)

  • 1. Optimizing cancer care for hepatocellular carcinoma at a safety-net hospital: The value of a multidisciplinary disease management team.
    Duininck G; Lopez-Aguiar AG; Lee RM; Miller L; Dariushnia S; Wu C; Alese OB; Lin JY; Wedd J; Adams A; Maithel SK; Russell MC
    J Surg Oncol; 2019 Dec; 120(8):1365-1370. PubMed ID: 31642056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Landscape of Hepatocellular Carcinoma : A US Safety Net Collaborative Analysis of Etiology of Cirrhosis.
    Lee RM; Gamboa AC; Turgeon MK; Yopp A; Ryon EL; Kronenfeld JP; Goel N; Wang A; Lee AY; Luu S; Hsu C; Silberfein E; Maithel SK; Russell MC
    Am Surg; 2020 Jul; 86(7):865-872. PubMed ID: 32721171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of a Voice Messaging System is Associated With Improved Time-to-Treatment and Overall Survival in Patients With Hepatocellular Carcinoma.
    Mokdad A; Browning T; Mansour JC; Zhu H; Singal AG; Yopp AC
    J Natl Compr Canc Netw; 2016 Jan; 14(1):38-46. PubMed ID: 26733553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis.
    Chinnaratha MA; Campbell K; Mathias R; McCormick RJ; Woodman RJ; Wigg AJ
    J Gastrointest Cancer; 2019 Dec; 50(4):888-893. PubMed ID: 30345486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
    J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival.
    Agarwal PD; Phillips P; Hillman L; Lucey MR; Lee F; Mezrich JD; Said A
    J Clin Gastroenterol; 2017 Oct; 51(9):845-849. PubMed ID: 28877082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hepatitis C treatment on long-term outcomes for patients with hepatocellular carcinoma: a United States Safety Net Collaborative Study.
    Turgeon MK; Lee RM; Gamboa AC; Yopp A; Ryon EL; Goel N; Wang A; Lee AY; Luu S; Hsu C; Silberfein E; Maithel SK; Russell MC
    HPB (Oxford); 2021 Mar; 23(3):422-433. PubMed ID: 32778389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.
    Tavakoli H; Robinson A; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
    Dig Dis Sci; 2017 Aug; 62(8):2174-2181. PubMed ID: 28474143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.
    Serper M; Taddei TH; Mehta R; D'Addeo K; Dai F; Aytaman A; Baytarian M; Fox R; Hunt K; Goldberg DS; Valderrama A; Kaplan DE;
    Gastroenterology; 2017 Jun; 152(8):1954-1964. PubMed ID: 28283421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunities to Improve Care of Hepatocellular Carcinoma in Vulnerable Patient Populations.
    Hoehn RS; Hanseman DJ; Dhar VK; Go DE; Edwards MJ; Shah SA
    J Am Coll Surg; 2017 Apr; 224(4):697-704. PubMed ID: 28069526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
    Kim NG; Nguyen PP; Dang H; Kumari R; Garcia G; Esquivel CO; Nguyen MH
    Cancer; 2018 Jun; 124(12):2588-2598. PubMed ID: 29624631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival.
    Leykum LK; El-Serag HB; Cornell J; Papadopoulos KP
    Clin Gastroenterol Hepatol; 2007 Apr; 5(4):508-12. PubMed ID: 17382601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.
    Yopp AC; Mansour JC; Beg MS; Arenas J; Trimmer C; Reddick M; Pedrosa I; Khatri G; Yakoo T; Meyer JJ; Shaw J; Marrero JA; Singal AG
    Ann Surg Oncol; 2014 Apr; 21(4):1287-95. PubMed ID: 24318095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
    Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
    Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of a Hepatocellular Carcinoma Screening Program for At-risk Patients Safety-Net Hospital: A Model for National Dissemination.
    Lee RM; Darby R; Medin CR; Haser GC; Mason MC; Miller LS; Staley CA; Maithel SK; Russell MC
    Ann Surg; 2022 Sep; 276(3):545-553. PubMed ID: 35837969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history and treatment trends in hepatocellular carcinoma subtypes: Insights from a national cancer registry.
    Jernigan PL; Wima K; Hanseman DJ; Hoehn RS; Ahmad SA; Shah SA; Abbott DE
    J Surg Oncol; 2015 Dec; 112(8):872-6. PubMed ID: 26603598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
    Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma.
    Mohsen W; Rodov M; Prakoso E; Charlton B; Bowen DG; Koorey DJ; Shackel NA; McCaughan GW; Strasser SI
    World J Gastroenterol; 2017 Apr; 23(15):2763-2770. PubMed ID: 28487614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.